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Abbreviations 
AJCC – American Joint Committee on Cancer 
APUD – Amine Precursor Uptake Decarboxylase 
BID – twice a day 
BM – Brain metastases 
CAV – Cyclophosphamide, doxorubicin and vincristine 
CRT – Chemoradiotherapy 
EORTC – European Organisation for Research and Treatment of Cancer 
EP – Etoposide and cisplatin 
ES – extensive stage 
Gy - Gray 
IARC – International Agency for Research on Cancer 
IASLC – International Association for the Study of Lung Cancer  
IPD – individual patient data 
LS – Limited stage 
MRI – Magnetic resonance imaging 
NCCN – National Comprehensive Cancer Network 
NCDB – National Cancer Data Base 
OID – once a day 
OR – Odds ratio 
OS – Overall survival 
PCI – Prophylactic cranial irradiation 
SEER – Surveillance, Epidemiology, and End Results 
SCLC – Small Cell Lung Cancer 
SRS – Stereotactic radiosurgery 
TRT – Thoracic radiotherapy 
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UICC – Union for International Cancer Control 
VA – Veterans Administration  
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Introduction  
Based on the IARC world cancer report 2014, lung cancer is the most frequent cancer 
worldwide with in excess of 1.8 million new cases (13% of cancer incidence) and 
approximately 1.6 million deaths (20% of cancer mortality), as estimated in 2012.1 In 2018, an 
estimated 234,030 people in the United States will be diagnosed with lung cancer of which an 
estimated 154,050 deaths will occur.2 In addition to increasing age, other factors associated 
with increased risk for lung cancer include prior history or current tobacco use, passive 
smoking, occupational exposure to arsenic, asbestos, chromium, beryllium, nickel and other 
agents, increased air pollution, family history of cancer and radiation exposure.3–11 Tumours of 
neuroendocrine origin account for approximately 20% of lung cancers with the absolute 
majority in the order of 14% constituting SCLC which is also called oat cell cancer.12 Small 
cell lung cancer is thought to stem from neuroendocrine cells (APUD cells) in the bronchus 
called Feyrter cells.13 Thus, these cells express multiple neuroendocrine markers and are 
associated with paraneoplastic syndromes and Cushing’s syndrome. SCLC is a highly 
aggressive, recalcitrant and lethal tumour with TP53 mutation in 70-90% of cases. At initial 
diagnosis about 30% of patients will present with SCLC restricted to the ipsilateral hemithorax, 
which can be safely encompassed within a radiation field. Historically, the Veterans 
Administration Lung Cancer Study Group defined a 2-stage classification and designated the 
above-mentioned group of patients as having limited stage (LS) disease. In contrast, patients 
with tumour dissemination beyond the ipsilateral hemithorax, including malignant pleural or 
pericardial effusion or hematogenous are said to have extensive stage (ES) disease.14,15 
However, the AJCC/UICC and IASLC revised the TNM staging for lung malignancies (8th 
edition) which became effective on January 1, 2018 and in comparing both systems, LS disease 
is defined as stage I-III (T any, N any, M0).16,17  
Chemotherapy is an essential pillar for treatment of SCLC regardless of disease stage. Since 
the mid 1980s, EP is considered standard chemotherapy regimen.18 This regimen displaced 
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alkylator/anthracycline-based regimens e.g. CAV regimen based on its favourable efficacy and 
toxicity profile.19–21 
Initially, early stage disease was treated with surgery; however, a Medical Research Council 
comparative trial randomised 144 patients with SCLC, diagnosed by biopsy and deemed 
operable (71/49%) vs. primary radical radiotherapy (73/51%) of cases. A complete resection 
was achieved in 48% of patients in the surgical arm and radiotherapy delivered in 85% of 
patients in the radiotherapy arm. The survival rates in the surgery vs. radiotherapy arm were 
4% and 10% at 24 months, 3% and 7% at 48 months, and 1% and 4% at 60 months, 
respectively.22 A 10-year follow-up demonstrated improved survival in favour of the 
radiotherapy arm. The authors concluded that radical radiotherapy conferred favourable 
survival outcomes in comparison to surgery in operable patients.23 Another trial published in 
1994 enrolled 328 patients with LS-SCLC with histologically confirmed small cell histology 
and who were deemed eligible for thoracotomy to either undergo pulmonary resection vs. 
observation for patients responding to induction chemotherapy with CAV for five cycles 
administered every 21 days.  All randomised patients received radiotherapy to the chest (50 Gy 
in 25 fractions) and PCI (30 Gy in 15 fractions). Sixty-six percent (217 patients) demonstrated 
good response. Sixty-six percent of responders (146 patients) were thus randomised to surgery 
(70 patients) vs. observation (76 patients). In the surgical series, a resection rate of 83% was 
achieved. No statistical significance was achieved between both arms. Median survival for all 
enrolled patients and randomised patients was 12 and 16 months, respectively. The results of 
the trial did not endorse inclusion of pulmonary resection to multimodality treatment of 
SCLC.24 Currently, there is some data supporting the use of surgery in patients with stage I 
disease under the premise that patients are comprehensively staged prior to surgical treatment. 
Following surgery, based on current guidelines, adjuvant chemotherapy is recommended in this 
setting based on a NCDB analysis by Yang et al.25  
SCLC is highly radiosensitive and TRT improves survival of patients. In 1992, two meta-
analyses demonstrated that the addition of TRT to chemotherapy was associated with improved 
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survival outcome in LS-SCLC. The first meta-analysis by Pignon et al. collected the individual 
patient data on all patients enrolled before December 1988 in randomised trials comparing 
chemotherapy alone with chemotherapy combined with TRT. A total of 13 trials and 2140 
patients of which 2103 patients were evaluated. The overall relative risk of death in the 
multimodal therapy arm vs. chemotherapy arm was 14% lower.26 Moreover, the meta-analysis 
by Warde et al. included 11 randomised trials and demonstrated an overall OR for benefit of 
TRT on 2-year survival of 1.53 (95% CI 1.3-1.76; p < 0.001). Intrathoracic tumour control was 
improved by 25.3% and TRT improved two-year survival by 5.4 %.27 Chemoradiotherapy was 
established as standard of treatment for LS-SCLC with the burden of evidence supporting early 
concurrent CRT endorsed by various studies and meta-analyses which have reported that early 
concurrent CRT is associated with favourable survival outcome in comparison to late 
concurrent/sequential CRT.28–34 The Japan Clinical Oncology Group Study 9104 study from 
Takada and colleagues strongly suggested that concurrent CRT with EP is more effective for 
the treatment of LS-SCLC than sequential CRT.31 De Ruysscher et al. defined a short time 
interval between the first day of any treatment and the last day of TRT as SER which correlated 
with OS.35 More recently, De Ruysscher published another meta-analysis of IPD from 12 trials 
(2668 patients) reporting improved 5-year survival in the early concurrent CRT vs. late 
concurrent CRT arm.36 In LS-SCLC, previous randomised trials have reported median survivals 
of 18-24 months and 40%-50% 2-year survival rates.28,31,37–39 Previously, the preponderance of 
evidence has reported no consistent survival benefit from administration of supplementary 
chemotherapeutic agents or other platinum-based combination regimens, increased dose 
density and intensity and maintenance chemotherapy.29,40–46 Regarding the fractionation 
schedule of TRT, the landmark intergroup 0096 trial endorsed twice-daily CRT commencing 
with the first chemotherapy cycle for patients with limited stage disease as significantly 
improved survival was conferred compared to once-daily CRT. In the study, patients were 
randomised to receive 45/1.8 Gy once-daily concurrent CRT or 45 Gy twice-daily concurrent 
CRT (1.5 Gy per fraction). Median survival was 19 and 23 months for the once- and the twice-
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daily group, respectively. Two- and five-year survival rates were 41% and 16% in the once-
daily radiotherapy vs. 47% and 26% for patients receiving twice-daily radiotherapy. However, 
this was at the cost of significantly increased treatment related toxicity e.g. significantly higher 
incidence of grade 3 oesophagitis occurred in the twice-daily vs. once-daily group (27% vs. 
11% ).39 However critics have argued whether the improved survival outcome was due to the 
higher biologically effective dose of TRT or the shorter start of any treatment until the end of 
radiotherapy. As such twice-daily CRT was not universally adopted for the above-mentioned 
reasons as well as operational issues pertaining to delivery of TRT twice per day. Consequently, 
the CONVERT trial by Faivre-Finn et al. was designed as a non-inferiority trial comparing 
higher dose once-daily radiotherapy with concurrent EP vs. the twice-daily regimen in the 
intergroup 0096 trial.47 In that study, the authors demonstrated non-significant differences in 
survival outcomes with once- vs. twice-daily CRT (median OS of 25 vs. 30 months in the once- 
vs. twice-daily group), 2-year and 5-year OS of 51% vs. 56%, and 31% vs. 34% in favour of 
the twice-daily group. Interestingly, toxicity was comparable and below the estimated 
threshold. However, increased grade 4 neutropenia with twice-daily CRT was detected. 
Moreover, no difference in grade 3-4 oesophagitis and grade 3-4 radiation pneumonitis was 
determined. As the trial had a non-inferiority design, the authors concluded that twice-daily 
CRT remain standard practice in this setting. However, once-daily CRT is a feasible option. 
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Prophylactic cranial irradiation in LS-SCLC 
Approximately 10% of SCLC patients present at diagnosis with BM with the cumulative risk 
rising to ³ 50% and an incidence of BM in up to 80% of subjects at autopsy.48,49 The brain is 
considered a sanctuary and the blood-brain barrier considered to protect the CNS from cytotoxic 
agents. The incapability of multiple systemic chemotherapeutic agents to penetrate the blood-
brain-barrier has hampered their use. Prophylactic cranial irradiation (PCI) was initially 
proposed for SCLC in 1973 due to the high incidence of BM in these patients and insufficient 
control with whole brain radiotherapy. Two meta-analyses showed benefit in terms of 
development of BM and survival.50,51  The first meta-analysis by Aupérin and colleagues 
demonstrated a modest but significant overall survival improvement from administration of PCI 
in complete responders which led to a 5.4% increase in 3-year survival. Moreover, PCI 
increased the rate of disease-free survival and decreased the cumulative incidence of BM.50 The 
second meta-analysis from Meert and colleagues incorporated 12 randomised trials with 1547 
patients. PCI significantly decreased the incidence of BM and conferred favourable survival 
outcome in complete responders. However, long-term neurologic sequelae was not sufficiently 
described.51 
However, the criticism levelled against both meta-analyses was they included studies in an era 
in which consequent neuroimaging was not mandated (pre-MRI era) and hence the role of PCI 
in the current age of ubiquitous availability of brain imaging might be subject to re-evaluation. 
Manapov et al. ascertained the role of a repeat cranial MRI before PCI. In a small retrospective 
study, BM were detected in 13/40 LS-SCLC patients who initially showed no evidence of BM 
on the first cranial MRI before primary treatment but developed brain failure on repeat MRI 
prior to PCI.52 Furthermore, Ozawa et al. deemed that PCI might be less effective in LS-SCLC 
provided extended management with cranial MRI and SRS were readily accessible.53 PCI has 
thus been the topic of recurring discussion as experts have serially debated its pros and cons in 
particular in relation to potential neurologic sequelae. Historically, prior to the publication by 
Aupérin et al., Cmelak and colleagues published a large survey with a total of 1231 responders, 
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including 628 (51%) radiation oncologists, 587 (48%) medical oncologists. Seventy-four 
percent of respondents recommended PCI in LS-SCLC (82% of radiation oncologists and 65% 
of medical oncologists). Only 30% of respondents recommended PCI for ES-SCLC. Medical 
oncologists believed more often than radiation oncologists that PCI causes late neurological 
sequelae (95% vs. 84%, p<0.05).54 
The NCCN guidelines recommend PCI in patients with LS-SCLC who demonstrate a good 
response to initial therapy based on the above-mentioned meta-analyses, which as stated 
included trials which did not incorporate routine brain imaging.55 The role of PCI in the small 
subset of patients with resected pathological stage I disease has previously been extensively 
discussed with the paucity of data suggesting a relatively low incidence of BM.56,57 Thus 
omission of PCI in this subgroup of patients may be a viable option. 
 
PCI in Elderly (³70 yr.) 
The proportion of elderly among all cases of SCLC has increased over the past 40 years.58 The 
number of elderly patients (>70 years) among all cases of SCLC increased as per the 
Surveillance, epidemiology, and end results database from 23% in 1975 to 44% in 2010. In 
general, elderly could be characterised by a lower performance status and higher comorbidity 
index. Earlier studies have shown that elderly fair significantly worse in comparison to younger 
SCLC patients.59,60 Also, a large cohort study regarding therapeutic whole brain irradiation 
reported significant toxicity such as neurocognitive dysfunction with memory loss in patients 
older than 70 years.61 In this context, elderly patients are the focus of research to reduce 
treatment-related toxicity of cranial irradiation and improve prognosis. 
There are no previous prospective randomised studies addressing the issue of PCI in elderly, 
however in the meta-analysis by Aupérin et al., patients ³65 yr. had a relative risk of death of 
0.79 (95% CI 0.60-1.03) and RR of BM of 0.37 (95% CI 0.24-0.59) which in both cases was 
lower than in patients <65 yr.50 Additionally, various retrospective studies have shown a 
significant improvement in survival in elderly patients62,63. In a study by Rule et al., PCI 
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resulted in a median survival of 12.0 months vs. 7.6 months in the non-PCI group as well as 
3yr. OS 13.2% vs. 3.1%.62 Similarly, Eaton et al. demonstrated using the SEER database that 
PCI conferred favourable survival outcome.63 The recent phase III CONVERT-Study included 
patients with LS-SCLC with 83 patients (15%) ³70 yr. and this data was presented at the 2016 
World Conference of Lung Cancer in Vienna, Austria and the final publication is still pending.47  
In the first publication, we defined an association between treatment response to multimodal 
therapy and survival parameters in LS-SCLC and compared survival parameters based on 
treatment response e.g. complete vs. partial remission. As previously extensively stated, the 
preponderance of evidence suggests that chemoradiotherapy with thoracic radiotherapy starting 
with the first or second cycle of CRT represents the standard treatment for LS-SCLC. In 
contrast, Sun et al. demonstrated that a delayed start of TRT (late TRT arm) to a total dose of 
52.5 Gy in 2.1 Gy daily fractions starting with the third cycle of chemotherapy (day 43) is 
statistically non-inferior to early TRT beginning on day 1 of the first cycle of chemotherapy 
(early TRT arm) [median OS 26.8 months vs. 24.1; HR 0.90; 95% CI 0.18–1.62 and median 
progression-free survival 11.2 months vs. 12.4; HR 1.10; 95% CI 0.37-1.84] and is associated 
with significantly favourable haematological toxicity profile, including neutropenic fever 
(10.2% vs. 21.6%;p= 0.02).64 In addition, no differences in remission rates and early vs. late 
irradiation arms were detected. However, favourable OS outcome was significantly associated 
with achievement of complete remission. Furthermore, Manapov et al. demonstrated in a 
previous publication that the duration of BM-free survival correlated with long-term outcome. 
Moreover, the response of the primary tumour to CRT correlated with the duration of BM-free 
survival in LS-SCLC.65 
The second publication sought to characterise the role of PCI in an actual heterogeneous LS-
SCLC cohort. Based on a previous publication by Manapov et al. published in 2008 which 
detected a significant incidence of BM in LS-SCLC patients who initially showed no signs of 
BM prior to primary treatment but showed evidence of BM on repeat MRI before PCI.52 Thus 
repeat MRI is recommended for LS-SCLC patients prior to PCI. Ozawa and colleagues 
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postulated that PCI may be less effective in LS-SCLC provided extended management with 
brain MRI and SRS was readily accessible.53 As previously extensively discussed, the landmark 
meta-analyses of PCI included trials in the pre-MRI era. Thus, critics have argued that its 
modest survival benefit might dissipate in the presence of comprehensive brain imaging as 
some have suggested that the improved survival outcome conferred by PCI may be attributed 
to treatment response of subclinical BM to cranial irradiation and not per se “PCI”. 
This conclusion was highlighted by a recent Japanese trial by Takahashi et al. in patients with 
extensive stage SCLC which has sparked renewed debate within the thoracic oncology 
community. Since the EORTC trial by Slotman et al. in 2007 which demonstrated a reduction 
in risk of BM, 1-year cumulative risk of BM of 14.6% and 40.4%, 1-year survival rate of 27.1% 
vs. 13.3% in the PCI vs. control group and an association of PCI with improved median disease-
free survival from 12.0 weeks to 14.7 weeks and median OS from 5.4 months to 6.7 months 
from randomisation, PCI was established as treatment standard in ES-SCLC.66  
The Japanese study by Takahashi et al. randomised 224 patients between 2009- 2013 to PCI vs. 
observation. On interim analysis of the first 163 enrolled patients, Bayesian predictive 
probability of PCI being superior to observation was 0.011%, resulting in early termination of 
the study due to futility. In the final analysis, median OS from randomisation was 11.6 and 13.7 
months in the PCI and observation arm, respectively. The authors concluded that PCI could be 
omitted in therapy responders provided these patients were followed comprehensively by serial 
brain imaging and radiotherapy be deferred till onset of BM.67  
The purpose of the second study was to demonstrate favourable survival outcome conferred by 
PCI in an actual heterogeneous cohort prodigiously staged with brain MRI. 
Summary 
Based on the results of our retrospective analyses, we defined the role of remission status in 
LS-SCLC solely treated with CRT and compared survival outcome in patients based on 
remission status. In the first study, remission status was significantly associated with tumour 
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control. Subsequently showing a clear association with overall survival. Furthermore, complete 
remission led to improved time to progression, distant metastasis-free survival and overall 
survival compared to patients with stable or progressive disease and especially patients with 
partial remission. 
The second study on assessing the efficacy of PCI in an actual LS-SCLC cohort continuously 
staged with cranial MRI. PCI was delivered exclusively in patients who demonstrated good 
response to primary treatment and no signs of BM on repeat MRI. Thus, we sought out to define 
the authentic preventative role of PCI in comparison to the landmark meta-analyses which 
included trials prior to the MRI era. Our results demonstrated a significant association between 
delivery of PCI in therapy responders and time to progression, brain metastasis-free survival 
and overall survival. 
Zusammenfassung 
Basierend auf den Ergebnissen unserer retrospektiven Analysen haben wir die Rolle des 
Remissionsstatus bei LS-SCLC Patienten, die mit primärer Radiochemotherapie behandelt 
wurden. Wir verglichen die Überlebensparameter in den verschiedenen Untergruppen von 
Patienten, die nach dem Remissionsstatus definiert wurden. Die erste Studie zeigte einen klaren 
Zusammenhang zwischen Remissionsstatus und Tumorkontrolle. Zudem konnte ein klarer 
Zusammenhang mit dem Gesamtüberleben nachgewiesen werden. Darüber hinaus führte eine 
vollständige Remission zu einer verbesserten Zeit bis zum Fortschreiten der Erkrankung, zu 
einem verbesserten Fernmetastasenfreien Überleben und letztendlich zu einem besseren 
Gesamtüberleben im Vergleich zu Patienten mit stabiler oder fortschreitender Erkrankung und 
insbesondere zu Patienten mit partieller Remission.  
Die zweite Studie zielte darauf ab, die Rolle der PCI in einer realen heterogenen LS-SCLC-
Patientenkohorte, die mit kranialer MRT umfassend untersucht wurde, zu untersuchen. PCI 
wurde ausschließlich bei Patienten eingesetzt, die auf die primäre Behandlung gut ansprachen 
und keine Anzeichen von BM bei wiederholter MRT zeigten. Daher haben wir versucht, die 
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authentische präventive Rolle der PCI im Vergleich zu den wegweisenden Meta-Analysen zu 
definieren, die Studien vor der MRI-Ära inkludierten. Unsere Ergebnisse zeigten einen 
signifikanten Zusammenhang zwischen der Verabreichung von PCI in Therapie-Respondern 
und der Zeit bis zur Progression, dem Überleben ohne Hirnmetastasen und dem 
Gesamtüberleben. 
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